Amylyx Pharmaceuticals (AMLX) Cash & Equivalents (2021 - 2026)

Amylyx Pharmaceuticals has reported Cash & Equivalents for 6 years, with the latest figure at $49.3 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 15.08% year-over-year to $49.3 million in Q2 2026; TTM through Jun 2026 was $49.3 million, a 15.08% decrease from a year earlier, with the FY2025 full-year figure at $226.7 million, up 192.86% from the prior year.
• Cash & Equivalents was $49.3 million for Q2 2026 at Amylyx Pharmaceuticals, down from $229.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $247.8 million in Q2 2023, with the low at $49.3 million in Q2 2026.
• Average Cash & Equivalents over 5 years is $125.5 million, with a median of $109.1 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2026: Cash & Equivalents tumbled 69.73% in 2024, then jumped 283.4% in 2026.
• Over 5 years, Cash & Equivalents stood at $62.5 million in 2022, then soared by 172.21% to $170.2 million in 2023, then tumbled by 54.53% to $77.4 million in 2024, then surged by 192.86% to $226.7 million in 2025, then plunged by 78.24% to $49.3 million in 2026.
• The last three Cash & Equivalents figures came in at $49.3 million (Q2 2026), $229.1 million (Q1 2026), and $226.7 million (Q4 2025), per Business Quant data.